You are here: Industry Insights > Market News > Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

CBZ-L-Valganciclovir

4-Bromo-3-nitroanisole

PF-680Adjustable Cellophane Tri-dimensiona Overwrapping Machine (with tear type)

2-Chlorophenothiazine

Flibanserin

its control software

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

expresspharmaMarch 12, 2021

Tag: Hikma , GSK , Egypt , Tunisia

Favorites

Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.

Hikma, which supplies generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, had said in January it was planning to buy those assets.

Previous:Vir, GSK to seek EUA for COVID-19 antibody therapy

Next:Enveric Biosciences acquires licence for Diverse Biotech’s novel molecules

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>